单位：[1]Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.[2]Department of Ophthalmology, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA, USA.[3]Merck & Co., Inc., South San Francisco, CA, USA.[4]Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China.[5]Shenzhen Key Laboratory of Ophthalmology, Shenzhen Eye Hospital, Jinan University, School of Optometry, Shenzhen University, Shenzhen, China.[6]Department of Ophthalmology, Charoenkrung Pracharak Hospital, Bangkok, Thailand.
Purpose: To evaluate the feasibility of using the Proximity Extension Assay (PEA) platform to detect biomarkers in vitreous and to compare the findings with results obtained with an electrochemiluminescent (ECL) sandwich immunoassay. Methods: Vitreous samples from patients with proliferative diabetic retinopathy (PDR) and non-diabetic controls were tested using two different proteomics platforms. Forty-one assays were completed with the ECL platform and 459 with the PEA platform. Spearman's rank correlation coefficient (r(s)) was used to determine the direction and strength of the relationship between protein levels detected by both platforms. Results: Three hundred sixty-six PEA assays detected the tested protein in at least 25% of samples, and the difference in protein abundance between PDR and controls was statistically significant for 262 assays. Seventeen ECL assays yielded a detection rate >= 25%, and the difference in protein concentration between PDR and controls was statistically significant for 13 proteins. There was a subset of proteins that were detected by both platforms, and for those the Spearman's correlation coefficient was higher than 0.8. Conclusions: PEA is suitable for the analysis of vitreous samples, showing a strong correlation with the ECL platform. The detection rate of PEA panels was higher than the panels tested with ECL. The levels of several proinflammatory and angiogenic cytokines were significantly higher in PDR vitreous compared to controls. Translational Relevance: This study provides new information on the yields of small-volume assays that can detect proteins of interest in ocular specimens, and it identifies patterns of cytokine dysregulation in PDR.
基金：
National Institutes of Health National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY002162, 1R01EY024004]; Research to Prevent BlindnessResearch to Prevent Blindness (RPB); That Man May See; Merck Sharp Dohme Corp.Merck & Company
第一作者单位：[1]Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.[2]Department of Ophthalmology, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA, USA.
通讯作者：
通讯机构：[1]Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.[2]Department of Ophthalmology, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA, USA.[*1]University of California, San Francisco, Department of Ophthalmology, 10 Koret Way, K301, San Francisco, CA 94143-0730, USA
推荐引用方式(GB/T 7714)：
Lamy Ricardo,Farber-Katz Suzette,Vives Franklin,et al.Comparative Analysis of Multiplex Platforms for Detecting Vitreous Biomarkers in Diabetic Retinopathy[J].TRANSLATIONAL VISION SCIENCE & TECHNOLOGY.2020,9(10):doi:10.1167/tvst.9.10.3.
APA：
Lamy Ricardo,Farber-Katz Suzette,Vives Franklin,Ayanoglu Gulesi,Zhao Tong...&Stewart Jay M.(2020).Comparative Analysis of Multiplex Platforms for Detecting Vitreous Biomarkers in Diabetic Retinopathy.TRANSLATIONAL VISION SCIENCE & TECHNOLOGY,9,(10)
MLA：
Lamy Ricardo,et al."Comparative Analysis of Multiplex Platforms for Detecting Vitreous Biomarkers in Diabetic Retinopathy".TRANSLATIONAL VISION SCIENCE & TECHNOLOGY 9..10(2020)
